2.0 CME/CE CREDITS
Multiple myeloma (MM) has a heterogeneous outcome. Progress in understanding the biology and molecular genetics of MM is responsible for the observed improvements in survival. Faculty will discuss the use of specific chromosomal abnormalities as well as the use of gene expression profiling (GEP) to risk-stratify MM patients. GEP has identified seven distinct subgroups of MM plasma cells with clinical characteristics that are known to be associated with poor prognosis and represent the framework for a new classification system. The information presented will allow the participants to understand the use of GEP in MM. GEP allows for risk-based strategies, thereby improving the clinical outcome. This technology is not limited to MM; the session will cover additional disease states where it has demonstrated utility.
You will learn to:
William T. Bellamy, RPh, PhD, HCLD
John W. Theus, MD, FCAP